SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending amid community excitement and increased trading volume, with holders expressing bullish sentiment and anticipating a significant pump. Discussions revolve around key resistance levels and the potential for new all-time highs, with some drawing comparisons to other meme coins. The community highlights its strong support and resilience during market fluctuations, reinforcing confidence in TOSHI's long-term potential.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst a mix of community frustration and hope for future gains, with some users discussing the potential for a price surge while others label it a "scam." The community is closely watching volume and potential catalysts, with some mentioning upcoming events and others expressing concern over stagnant price action compared to other meme coins like $PEPE and $DOGE. Sentiment is divided, with some users remaining bullish and highlighting the strength of the Shiba Inu community.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is trending as it gains traction within the Phantom Wallet community. The community is excited about its potential, referring to it as a "gem" with "rocket vibes" and anticipating a breakout. However, some users are also expressing concerns, labeling it as a potential scam.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its recent FDA approval for leukemia drug Revuforj, overshadowed by a new boxed warning for potential heart rhythm risks, sparking debates about the drug's safety profile versus its efficacy. The community is weighing the significance of these warnings against the drug's potential benefits for patients with limited treatment options, while also considering the competitive landscape with companies like KURA. Some traders speculate about a potential buyout, given the company's strong pipeline and recent milestones.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol ($VIRTUAL) is trending amid community discussions about its potential, use cases, and AI agent ecosystem. Recent price movements and listing on Robinhood are sparking bullish sentiment, while some traders express concerns about pump-and-dump dynamics and potential corrections. The focus remains on the utility of AI agents within the Virtuals ecosystem.

VanEck ETF Trust - VanEck Social Sentiment ETF

VanEck Social Sentiment ETF

BUZZ is trending as the market speculates on potential rebalancing moves, with community members suggesting which stocks should be added or removed. The ETF, which tracks social sentiment, has some questioning its holdings and overall performance versus benchmarks. Some traders are using it as a gauge of overall retail investor sentiment.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential catalysts and the token's price action relative to Bitcoin and other cryptocurrencies. Some speculate on upcoming news and its impact, while others express frustration with XRP's price movements and long-term prospects. Discussions also involve potential partnerships and institutional adoption.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining attention as community members rally around its unique branding and real-world partnerships, including sponsored athletes like Karolina Arm, a pro MMA fighter. The community is excited about Arm's upcoming fight and appreciates the team's consistent efforts. Many highlight that $SLAP is more than just a meme; it represents a lifestyle and a dedicated community.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending following the release of strong revenue growth for fiscal year 2025, sparking excitement around its small float. Community members are actively discussing the potential for a short squeeze and comparing it to previous high-flying stocks, while also noting high insider ownership. Traders are closely watching key levels, anticipating a significant move.

Roundhill ETF Trust - Roundhill Meme Stock ETF

Listed Funds Trust - Roundhill MEME ETF

The $MEME ETF is gaining attention as traders discuss its holdings and performance relative to individual meme stocks like $BYND. Community members are debating whether the ETF's price accurately reflects the performance of its top holdings, with some questioning if the fund is a worthwhile investment. Chatter includes speculation about potential additions like $NEGG and possible short squeeze opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacira (PCRX) Tops Q2 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Pacira BioSciences Inc (PCRX) traded 19% higher on Tuesday morning, following upward price target revisions by multiple brokerages following a patent litigation settlement.Pacira <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-announces-settlement-us-patent-litigation">announced</a> on Monday that it has settled its litigations related to patents for EXPAREL or bupivacaine liposome injectable suspension, a long-acting local pain reliever.As part of the settlement, Pacira agreed to provide Fresenius Kabi USA, LLC with a license to Pacira’s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date sometime in early 2030.Pacira also agreed to provide Fresenius with a license to Pacira’s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.Pacira CEO Frank D. Lee said Monday that the settlement agreement provides “clarity” around EXPAREL exclusivity.Meanwhile, H.C. Wainwright raised the firm's price target on Pacira to $65 from $48 while keeping a ‘Buy’ rating on the shares.The firm opined that the Street is "wildly overestimating" the company's Exparel generic risk and "dramatically underpricing" Pacira shares, according to TheFly.RBC Capital also raised its price target on Pacira to $26 from $22 on Tuesday and maintained a “Sector Perform” rating on the shares.Pacira BioSciences’ settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise, the analyst said.It brings needed clarity and five years of protection to potentially realize the benefits of internal drivers, the analyst told investors in a research note.Truist also raised its price target on Pacira to $28 from $25 and kept a ‘Hold’ rating on the shares. The firm now envisions peak Exparel sales of $740 million by 2029.On Stocktwits, retail sentiment about PCRX jumped from ‘extremely bearish’ to ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:650/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_08_at_10_20_15_AM_png_84a9d54519.webp" alt="PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits" width="650" height="150"><figcaption>PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PCRX">PCRX Shares</a> have risen nearly 49% this year but have fallen over 4% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cvs-health-appoints-new-cfo-chief-medical-officer/chflzodRbJf">CVS Health Appoints New CFO, Chief Medical Officer: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pacira Biosciences Stock Rises On Multiple Price Target Upgrades: Retail Sentiment Soars

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.

Equity

Shares of Pacira BioSciences Inc. soared over 22% in extended trading on Monday after the company said it had resolved a legal case over its long-acting pain medication.&nbsp;Pacira has settled litigation with Germany's Fresenius Kabi and its partners over patents related to Exparel, which reportedly provides&nbsp;pain&nbsp;relief for up to 72 hours after surgery.As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030, when it will be allowed limited entry into the U.S. market under a confidential volume cap.The licensed volumes will start in the high single-digit percentage range and gradually increase each year, reaching the high thirty percent by the agreement's final years.&nbsp;Still, Fresenius will be permitted to sell unlimited volumes of its generic version starting in 2039, before Pacira's last-listed Exparel patent expires in July 2044.&nbsp;On Stocktwits, sentiment for Pacira jumped into ‘extremely bullish’ levels late Monday, accompanied by a 50% jump in message volume over the last 24 hours.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/PCRX_sentiment_and_message_volume_as_of_April_7_png_47dd0566cd.webp" alt="PCRX sentiment and message volume as of April 7.png" width="1318" height="316"><figcaption>PCRX sentiment and message volume as of April 7. | source: Stocktwits</figcaption></figure>"The settlement terms are notably favorable for Pacira. They've secured full exclusivity until early 2030 - providing at least 5 more years of uncontested market presence," said one user.<stembedurl>https://stocktwits.com/GoldKing23/message/610799845</stembedurl>"Market hates uncertainty—this clears the deck," posted another.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/610799401</stembedurl>In December 2024, Pacira was granted a U.S. Patent covering the chemical composition of Exparel.That same month, the company filed a lawsuit in Illinois to defend Exparel against generic challengers.<a href="https://stocktwits.com/symbol/PCRX">Pacira’s stock</a> has gained more than 20% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud...

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of...

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX Pacira BioSciences, Inc...

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire NEW...

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX PACIRA...

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira BioSciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PCRX
Pacira BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PCRX News

PCRXPacira BioSciences Inc